Genentech/B-ORG Inc./I-ORG said/O the/O West/O German/O distributor/O of/O its/O heart/O drug/O TPA/O reached/O a/O joint/O marketing/O agreement/O with/O a/O subsidiary/O of/O Hoechst/B-ORG AG/I-ORG ,/O which/O makes/O the/O rival/O anti-clotting/O agent/O streptokinase/O ./O
The/O biotechnology/O concern/O said/O the/O agreement/O between/O its/O longtime/O West/O German/O distributor/O ,/O Boehringer/B-ORG -/I-ORG Ingleheim/I-ORG 's/I-ORG Dr./B-ORG Karl/I-ORG Thomae/I-ORG G.m.b.H./I-ORG subsidiary/O ,/O and/O Hoechst/B-ORG 's/O Behringwerke/B-ORG subsidiary/O was/O an/O attempt/O to/O expand/O the/O market/O for/O blood/O -/O clot/O drugs/O in/O general/O ./O
A/O Genentech/B-ORG spokeswoman/O said/O the/O agreement/O calls/O for/O Hoechst/B-ORG to/O promote/O TPA/O for/O heart/O patients/O and/O streptokinase/O for/O other/O clot/O -/O reducing/O purposes/O ./O
